Updates & Developments

October 2018

Health Canada approves Tegsedi (inotersen) for sale in Canada for the treatment of polyneuropathy in adult patients with hATTR amyloidosis

February/March 2019

Patient input for Tegsedi and Onpattro (patisiran) provided to the Canadian Agency for Drugs and Technologies in Health (CADTH) Common Drug Review (CDR) and l’Institut national  d’excellence en santé et services sociaux (INESSS)

June 2019

Health Canada approves Onpattro (patisiran) for sale in Canada for the treatment of polyneuropathy in adult patients with hATTR amyloidosis

CDR recommends Onpattro be publicly funded (with criteria and conditions) for the treatment of polyneuropathy in adult patients with hATTR amyloidosis

August 2019

INESSS recommends Tegsedi be added to the list of drugs covered by the prescription drug insurance plan in Quebec

September 2019

INESSS recommends Onpattro be added to the list of drugs covered by the prescription drug insurance plan in Quebec

November 2019

The manufacturer of Tegsedi begins active negotiations with the pan-Canadian pharmaceutical alliance (pCPA)

December 2019

CDR recommends Tegsedi be publicly funded (with criteria and conditions) for the treatment of polyneuropathy in adult patients with hATTR amyloidosis

The manufacturer of Onpattro begins active negotiations with pCPA

January 2020

Health Canada approves Vyndaqel™ (tafamidis) for sale in Canada for the treatment of transthyretin amyloid cardiomyopathy in adult patients

February 2020

CDR recommends Vyndaqel be publicly funded (with criteria and conditions) for the treatment of transthyretin amyloid cardiomyopathy in adult patients

March 2020

HAC has first meeting with pCPA to discuss importance of swift pricing negotiations for Tegsedi and Onpattro

INESSS recommends Vyndaqel not be added to the list of drugs covered by the prescription drug insurance plan in Quebec

HAC officially launches its #stophATTRnow advocacy campaign calling for swift publicly funded access to all Health Canada-approved treatment options for hATTR amyloidosis

April 2020

pCPA successfully completes negotiations for Tegsedi by signing a Letter of Intent (LOI)

May 2020

HAC initiates dialogue with all provincial drug plans to discuss the importance of immediate access to all Health Canada-approved treatment options for hATTR amyloidosis

Tweet

We want to hear from you!!

We hope you will join our advocacy efforts by using the tools on this website. Please reach out to Hereditary Amyloidosis Canada (HAC) with any questions about our work, to share your hATTR amyloidosis stories, or to tell us how we can make this site even better.

Share This
Copy link
Powered by Social Snap